All In Biotech

Drug Trial Radar · NCT04564612

Study of BIIB091 Formulations in Healthy Participants

An Open-Label, Pharmacokinetic Study to Evaluate the Pharmacokinetics and Relative Bioavailability of BIIB091 Formulations and to Assess the Impact of Food, a Proton Pump Inhibitor and CYP3A4 Inhibitor on BIIB091 Exposure Using the Selected Formulation in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Sep 28, 2020

Primary completion

Sep 7, 2022

Study completion Sep 7, 2022

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of this study are: to evaluate the pharmacokinetic (PK) profiles of BIIB091 modified release (MR) formulations in healthy participants after single dose administration in the fasted state (Part 1); to evaluate the PK profile of the BIIB091 immediate release (IR) tablet formulation in healthy participants after single dose administration (Part 1B); to determine the relative bioavailability of single doses of the selected BIIB091 regimen in healthy participants taking a proton pump inhibitor (PPI) compared to healthy participants not taking a PPI, to determine the relative bioavailability of single doses of the selected BIIB091 regimen in healthy participants taking a cytochrome P450 (CYP)3A4 inhibitor compared to healthy participants not taking a CYP3A4 inhibitor (Part 2); to evaluate the PK of the selected BIIB091 regimen in healthy participants after multiple dose administration (Part 3). The secondary objectives of this study are: to determine the relative bioavailability of a single dose of the BIIB091 MR formulations compared to that of the IR drug in capsule (DiC) reference formulation in healthy participants in the fasted state, to assess the safety and tolerability of single doses of BIIB091 when administered as MR formulations in healthy participants in the fasted state (Part 1); to determine the PK of a single dose of the BIIB091 IR tablet formulation in the fed and fasted state in healthy participants, to evaluate the PK profiles of the BIIB091 IR tablet formulation in healthy participants after administration of divided total daily doses over a 24 hour period in the fasted or fed state, to determine the relative bioavailability of a single dose or divided dose of the BIIB091 IR tablet formulation compared to that of the IR DiC reference formulation in healthy participants in the fasted state, to determine the PK of a single or divided dose of the BIIB091 IR tablet formulation administered with an alternative meal composition in healthy participants, to assess the safety and tolerability of a single or divided dose of BIIB091 when administered as the IR tablet formulation and IR DiC reference formulation in healthy participants in fed or fasted state (Part 1B); to confirm the PK profiles of the selected BIIB091 regimen in healthy participants after single dose administration, and to establish a reference exposure for the assessment of drug interaction, to assess the safety and tolerability of single doses of BIIB091 when administered as the selected BIIB091 regimen in healthy participants taking a PPI, to assess the safety and tolerability of single doses of BIIB091 when administered as the selected BIIB091 regimen in healthy participants taking a CYP3A4 inhibitor (Part 2); to assess the safety and tolerability of multiple doses of BIIB091 when administered as the selected BIIB091 regimen in healthy participants (Part 3).

Conditions

  • Healthy Volunteers

Interventions

  • BIIB091Drug

    Administered as specified in the treatment arm

  • RabeprazoleDrug

    Administered as specified in the treatment arm

  • ItraconazoleDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 1B: Time Prior to the First Measurable Concentration (Tlag) of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5
  2. Parts 1, 1B and 3: Time of Maximum Observed Concentration (Tmax) of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5; Part 3: Up to Day 14
  3. Parts 1, 1B and 3: Maximum Observed Concentration (Cmax) of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5; Part 3: Up to Day 14
  4. Parts 1 and 1B: Plasma Concentration at 12 Hours (C12h) of BIIB091Time frame: Parts 1 and 1B: 12 hours post-dose (Day 1)
  5. Parts 1 and 1B: Plasma Concentration at 24 Hours (C24h) of BIIB091Time frame: Parts 1 and 1B: 24 hours post-dose (Day 2)
  6. Parts 1 and 1B: Area Under the Curve from Time 0 to 12 Hours Post-Dose [AUC(0-12h)] of BIIB091Time frame: Parts 1 and 1B: Up to 12 hours post-dose (Day 1)
  7. Parts 1 and 1B: Area Under the Curve from Time 0 to 24 Hours Post-Dose [AUC(0-24h)] of BIIB091Time frame: Parts 1 and 1B: Up to 24 hours post-dose (Day 2)
  8. Parts 1 and 1B: Area Under the Curve from Time 0 to the Time of Last Measurable Concentration [AUC(0-last)] of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5
  9. Parts 1, 1B and 3: Area Under the Curve from Time 0 Extrapolated to Infinity [AUC(0-inf)] of BIIB091Time frame: Part 1: Post-dose at multiple time points up to Day 4; Part 1B: Post-dose at multiple time points up to Day 5; Part 3: Post-dose at multiple time points up to Day 14
  10. Parts 1 and 1B: Area Under the Curve from Time of the Last Measurable Concentration to Infinity as a Percentage of the Area Under the Curve Extrapolated to Infinity (AUC%extrap) of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5
  11. Parts 1, 1B and 3: Terminal Elimination Half-Life (T1/2) of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5; Part 3: Up to Day 14
  12. Parts 1, 1B and 3: First Order Rate Constant Associated with the Terminal (Log-Linear) Portion of the Curve (Lambda-z) of BIIB091Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5; Part 3: Up to Day 14
  13. Parts 1 and 1B: Total Body Clearance of BIIB091 Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable (F) is Unknown (CL/F)Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5
  14. Parts 1 and 1B: Apparent Volume of Distribution of BIIB091 Based on the Terminal Phase Calculated Using AUC(0-inf) After a Single Extravascular Administration Where F is Unknown (Vd/F)Time frame: Part 1: Up to Day 4; Part 1B: Up to Day 5
  15. Part 2: Relative Bioavailability of BIIB091 Based on Cmax (Frel Cmax) of BIIB091 Dosed With and Without Proton Pump Inhibitor (PPI)Time frame: Part 2: Up to Day 5
  16. Part 2: Relative Bioavailability of BIIB091 Based on AUC(0-last) [Frel AUC(0-last)] of BIIB091 Dosed With and Without PPITime frame: Part 2: Up to Day 5
  17. Part 2: Relative Bioavailability of BIIB091 Based on AUC(0-inf) [Frel AUC(0-inf)] of BIIB091 Dosed With and Without PPITime frame: Part 2: Up to Day 5
  18. Part 2: Frel Cmax of BIIB091 Dosed With and Without Cytochrome P450 (CYP) 3A4 InhibitorTime frame: Part 2: Up to Day 5
  19. Part 2: Frel AUC(0-last) of BIIB091 Dosed With and Without CYP3A4 InhibitorTime frame: Part 2: Up to Day 5
  20. Part 2: Frel AUC(0-inf) of BIIB091 Dosed With and Without CYP3A4 InhibitorTime frame: Part 2: Up to Day 5
  21. Part 3: Concentration at the End of the Dosing Interval (Ctrough) of BIIB091Time frame: Part 3: Up to Day 14
  22. Part 3: Area Under Curve Observed at the End of the Dosing Interval (AUCtau) of BIIB091Time frame: Part 3: Up to Day 14
  23. Part 3: Plasma Concentration Observed at the End of the Dosing Interval (Ctau) of BIIB091Time frame: Part 3: Up to Day 14
  24. Part 3: Minimum Observed Concentration (Cmin) of BIIB091Time frame: Part 3: Up to Day 14
  25. Part 3: Average Concentration (Cave) of BIIB091Time frame: Part 3: Up to Day 14
  26. Part 3: Peak to Trough FluctuationTime frame: Part 3: Up to Day 14
  27. Part 3: Accumulation Ratio Based on Cmax/Cmax Single Dose (AR Cmax)Time frame: Part 3: Up to Day 14
  28. Part 3: Accumulation Ratio Based on AUCtau/AUCtau Single Dose (AR AUCtau)Time frame: Part 3: Up to Day 14
  29. Part 3: Total Body Clearance Calculated Using AUCtau After Repeated Extravascular Administration Where F is Unknown (CL/Ftau)Time frame: Part 3: Up to Day 14
  30. Part 3: Apparent Volume of Distribution Based on the Terminal Phase Calculated Using AUCtau After Extravascular Administration Where F is Unknown (Vd/Ftau)Time frame: Part 3: Up to Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.